It ended in less than two months left in 2016，Take a closer look at the first three seasons of children's drug -related pharmaceutical companies，Half of Xiyuan。8 A -share listed pharmaceutical companies，Jichuan Medicine、Guizhou Belle、The operating income and net profit of Kangzhi Pharmaceuticals have positively increased。

 

 

  & gt; & gt; & gt;

 

  Jichuan Pharmaceutical

 

  Jichuan Pharmaceutical Product Line Focus on Pediatrics、Breathing、Digestion and other fields，Among them, the exclusive products of pediatric products in pediatrics and clear heat granules are the best -selling varieties in the market。According to the Midnet My stake betting appMy stake betting appdata, it shows，In 2015, in my country's urban public hospital、The Pediatric Pharmaceutical Pharmaceutical Market of the Public Hospital of the County -level Public Hospital is all TOP1 products。

 

 

  Data display，Jichuan Pharmaceutical's operating income in the first three quarters of this year remains a growth of more than 30%，and the net profit remains more than 20%increase，The overall development momentum is stable and promoted。The company's operating income in the first three quarters of 2016 was 3.506 billion yuan，The growth rate drops slightly to 24.5%，net profit is 676 million yuan，The growth rate rose to 35.51%。

 

  Guizhou Belle

 

  Guizhou Bailing products involve cardiovascular and cerebrovascular categories、Cough、Cold category and children。Pediatric Chai Gui Anti -heating particles are one of the company's main profitable products，According to the Midnet My stake betting appMy stake betting appdata, it shows，In 2015, in urban public hospitals and county -level public hospitals in pediatric patent medicine markets，This product is squeezed into the top five。A competitive enterprise of Pediatric Chai Gui Anti -heating Granules There are two，In 2015, the market share of this product of Bailing, Guizhou is 18.28%。

 

 

  Guizhou Belle compared with the same period of the first three quarters of 2016，Operating income and net profit have a trend of slow growth，Where，Business income exceeds 1.5 billion yuan，Net profit also exceeded 300 million yuan。

 

  The company said，Current production and operation is normal，Sales team stable，Sales of main products continue to increase and stable growth，It is expected that the performance will remain steadily。2016's net profit changes belonging to shareholders of listed companies will be 450 million to 580 million yuan，Net profit changes are 10%～ 40%，The overall development trend steadily advances。

 

  Shan Dahuat

 

  subsidiary Dain Pharmaceutical Focus on the field of children's treatment and health care，Main Product Yi Kexin (Vitamin AD Det) is deeply praised by consumers，There is a good brand influence in the market。

 

  More than 10 competitive companies of vitamin AD drops，Daine Pharmaceutical's Vitamin AD Drops are in public hospitals in my country's urban public、County -level public hospital、City Community、The four chemicals of vitamin A and vitamin D (including the compound preparation of the two) market pattern of the four chemical drugs in the township and township health centers ranked sixth。

 

 

  Shan Dahuat's overall performance in 2016，Indeed, it has made great progress than last year。

 

  The annual report in the first half of this year mentioned，Dain Pharmaceutical Grabbing a good opportunity for children's pharmaceutical development，Continue to strengthen innovation capabilities，Timely adjusting sales strategies for market changes，Strengthen academic promotion and brand marketing，Good business performance in the first half of the year。A good upward momentum continued to the third quarter，Business income increased by 36.9%over the same period last year，and net profit growth rate is as high as 92%。

 

  Kangzhi Pharmaceutical

 

  The company is mainly engaged in the research and development of children's medication、Production and sales，At present。

 

 

  Kangzhi's Pharmaceuticals in 2016 surrounds the persistence & ldquo; children's great health strategy & rdquo; and & ldquo; boutique strategy & rdquo;stake sports betting appMy stake betting app，Improve Kangzhi Children's Pharmaceutical Brand; Strengthen the product market access work，Realize marketing breakthrough; optimize the supply chain system，Reduce operating costs，To enhance the company's competitiveness，This strategic deployment has been well developed and achieved good results，The operating income and net profit of the first three quarters have been greatly improved compared to the same period last year，Business income exceeded the 300 million yuan mark，The growth rate exceeds 37%。

 

  The company said，The system and mechanism of the development of new product development and special technology development of children's drugs will be further established，Give full play to the role of professional and technical personnel and expert consultants，Strengthen the demonstration of new drugs and internal approval，and strengthen deep technical cooperation with strong drug research units at home and abroad，At the same time in the development of new products，Pay attention to the product chief、、Short -term combination，and actively promote the secondary development of the listed products in accordance with market demand。

 

  & gt; & gt; & gt;

 

  Sunflower Pharmaceutical

 

  Sunflower Pharmaceutical Industry has been used in the digestive system、Children's medication、Breathing and cold medicine、Gynecological Medicine、Rheumatoid Bone Diseases、Six drugs in the six drugs of cardiovascular and cerebrovascular drugs，and have been involved in the field of great health。

 

  Company & ldquo; Little Sunflower & RDQUO; Children's medicine brands have a wide popularity in the field of children's medication，Among them, the best -selling product pediatric pulmonary heat cough and asthma liquid is one of the top ten products in the pediatric medicine market of urban public hospitals in my country in 2015。

 

 

  Data display，This year's overall operating income of Sunflower Pharmaceuticals has risen to slow，There is a trend of decline in net profit，The operating income of Sunflower Pharmaceutical in the third quarter was 2.129 billion yuan，growth rate is 0.49%，Net profit of 123 million yuan，The growth rate is -38.54%。

 

  The company's expected，2016's net profit changes belonging to shareholders of listed companies are 184 million yuan to 337 million yuan，Net profit changes -40.00%～ 10.00%，The reason for the change of performance is that the policy adjustment in the field of pharmaceutical circulation has brought stake online sports bettingStake Sports Bettinggreater uncertainty to corporate performance。

 

  Jianmin Group

 

  Company product focusing on pediatrics、Gynecology、Elderly and other treatment areas，The main products of pediatrics are exclusive varieties of Longmu Zhuang Bone Granules、Pediatric Baotangkang Granules、Pediatrics to declare lung cough particles, etc.。

 

  Pediatric Baotangkang Granules is one of the top ten products in the pediatric pharmaceutical market of the township health home in 2015，There are two competition companies，Jianmin Group occupies the largest market share，More than 68%。

 

 

  Jianmin Group mentioned in the third quarter report of the 2016 2016，Business income increased by 14.05%，Mainly the company's pharmaceutical business increased by 15.88%，The pharmaceutical industry increased by 10.72%，But compared to the same period last year，Operating income growth rate has not changed much，The trend of decline in net profit。

 

  Yabao Industry

 

  Yabao Pharmaceuticals strives to create children's health brands in the pharmaceutical industry，Forms & ldquo; Ding Gui & RDQUO; brand as the leading pediatric series of medicines and health products。

 

  As mentioned in the "Clear Announcement on Media Report" released by Yabao Pharmaceuticals on November 2，The company is doing the terminal pull mode，Flating the channel sales，Company resources will tilt towards the terminal，Therefore, since the second quarter, the company has taken the initiative to reduce the reserve inventory of the original dealer channel by restricting the delivery of dealers。

 

 

  Among them, the company's high -haired product Ding Guier's umbilical patch is limited and shipped, which affects sales revenue by 58.06%，The gross profit of this product decreased by 244 million yuan，The main reason for the decline in profit in the first three quarters of the company。

 

  Hansen Pharmaceutical

 

  Hansen Pharmaceutical's main business is a traditional Chinese patent medicine preparation、Chemical medicine、R & D of medical preparations、Production and sales，Gradually involved in the field of hospital。

 

  Exclusive product Simuli Decoction Oral Liquid Line entered the urban public hospital in my country last year、The top five of the three major pediatric pharmaceutical markets of the county -level public hospitals and the township health centers，The status of the drug in the market is quite stable。

 

 

  Hansen Pharmaceutical's operating income growth in the first three quarters of 2016 slowed down，There is a decline in net profit。

 

  Company said，It is expected stake sports betting appthat stake betting appthe net profit changes belonging to the shareholders of listed companies in 2016 are 78.46 million yuan to 107.88 million yuan，Net profit changes are -20.00%to 10.00%。The reasons for the decline in performance compared with the same period last year，Including an increase in the company depreciation fee，Bank deposit interest decrease，Marketing expenses increase，Increased investment in the early stage of the subsidiary，Affected by the macro operating environment at the same time，Especially unfavorable factors such as the decline in national medical security premiums and some bidding prices。

 

  In recent years，The wind of the policy blows towards children's medication，The latest published "& ldquo; Healthy China 2030 & rdquo; Planning Outline" also mentioned & ldquo; guarantee children's medication & rdquo;，At present, children's medicine in the industry can be described as dazzling stars。But，For children's medicine manufacturers，pressure developed by new products、The problems caused by policy adjustment in the circulation field have become the status quo that they must face，The front road is not smooth sailing。Who can submit a satisfactory transcript for this year，We wait and see。